Common Equity (Annual)

Common Equity: The sum of all common equity items.

Cytokinetics, Incorporated (CYTK) had Common Equity of $-659.62M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$88.04M
Net Income	$-784.96M
Cost of Goods Sold	--
Gross Profit	$88.04M
Operating Expenses	$700.30M
Operating Income	$-612.26M
Non-Operating Income/Expense	$-172.70M
Pre-Tax Income	$-784.96M
Normalized Pre-Tax Income	$-784.96M
Income after Taxes	$-784.96M
Income from Continuous Operations	$-784.96M
Consolidated Net Income/Loss	$-784.96M
Normalized Income after Taxes	$-784.96M
EBIT	$-612.26M
EBITDA	$-602.13M
Weighted-Average Shares Outstanding (Basic)	120.10M
Weighted-Average Shares Outstanding (Diluted)	120.10M
Earnings per Share (EPS) (Basic)	$-6.54
Earnings per Share (EPS) (Diluted)	$-6.54
Balance Sheet Financials
Current Assets	$916.98M
Property, Plant, and Equipment	$79.19M
Long-Term Assets	$507.56M
Total Assets	$1.42B
Current Liabilities	$202.45M
Long-Term Debt	$1.12B
Long-Term Liabilities	$1.88B
Total Liabilities	$2.08B
Common Equity	$-659.62M
Tangible Shareholders Equity	$-659.63M
Shareholders Equity	$-659.62M
Common Shares Outstanding	122.94M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-510.01M
Cash Flow from Investing Activities	$16.67M
Cash Flow from Financial Activities	$524.46M
Beginning Cash	$95.23M
End Cash	$125.63M
Increase/Decrease in Cash	$30.40M
Stock-Based Compensation	$112.29M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.53
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	2.45
Debt to Equity Ratio	-1.75
Gross Margin	100.00%
Operating Margin	-695.44%
EBIT Margin	-695.44%
EBITDA Margin	-683.94%
Pre-Tax Profit Margin	-891.60%
Profit Margin	-891.60%
Free Cash Flow	$-534.82M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.06
Inventory Turnover	--
Receiveable Turnover	4.96
Days Sales in Receivables	73.65
Return on Equity	119.00%
Return on Tangible Equity	119.00%
Return on Assets	-55.10%
Return on Investments	-172.00%
Book Value Per Share	$-5.37
Free Cash Flow per Share	$-4.45
Operating Cash Flow per Share	$-4.25

Data from Zacks Investment Research, Inc.